stoxline Quote Chart Rank Option Currency Glossary
  
aTyr Pharma, Inc. (LIFE)
1.9  0.05 (2.7%)    06-04 16:00
Open: 1.86
High: 1.95
Volume: 267,893
  
Pre. Close: 1.85
Low: 1.82
Market Cap: 131(M)
Technical analysis
2024-06-17 5:24:45 PM
Short term     
Mid term     
Targets 6-month :  2.44 1-year :  2.85
Resists First :  2.08 Second :  2.44
Pivot price 1.85
Supports First :  1.77 Second :  1.58
MAs MA(5) :  1.88 MA(20) :  1.84
MA(100) :  1.76 MA(250) :  1.68
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  53.7 D(3) :  49.4
RSI RSI(14): 60.8
52-week High :  2.45 Low :  1.08
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LIFE ] has closed below upper band by 20.2%. Bollinger Bands are 2.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.07 - 2.08 2.08 - 2.09
Low: 1.85 - 1.86 1.86 - 1.87
Close: 1.97 - 1.98 1.98 - 1.99
Company Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Headline News

Sat, 15 Jun 2024
aTyr Pharma (NASDAQ:LIFE) Now Covered by Analysts at StockNews.com - Defense World

Wed, 12 Jun 2024
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know - Yahoo Movies Canada

Tue, 11 Jun 2024
aTyr Pharma (NASDAQ:LIFE) Shares Cross Above Two Hundred Day Moving Average of $1.65 - MarketBeat

Tue, 11 Jun 2024
aTyr Pharma (NASDAQ:LIFE) Stock Crosses Above 200-Day Moving Average of $1.65 - Defense World

Wed, 05 Jun 2024
Insider Spends US$88k Buying More Shares In aTyr Pharma - Simply Wall St

Tue, 04 Jun 2024
aTyr Pharma, Inc. (NASDAQ:LIFE) Director Timothy Coughlin Acquires 50000 Shares of Stock - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 69 (M)
Held by Insiders 6.712e+007 (%)
Held by Institutions 2.6 (%)
Shares Short 383 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.808e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 79.1 %
Return on Equity (ttm) -29.4 %
Qtrly Rev. Growth 588000 %
Gross Profit (p.s.) 0
Sales Per Share -46.74
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -55 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 1.9
Stock Dividends
Dividend 0
Forward Dividend 343410
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android